von Tobias Borgers | März 21, 2024 | Continuous Manufacturing
Today’s drug products demand the utmost versatility and flexibility in equipment to accommodate both large-scale and small batch manufacturing, containment requirements for highly potent drug products and complex biologics, and operating efficiency. Leveraging...
von Tobias Borgers | März 21, 2024 | Continuous Manufacturing
Patient safety is an Industry 4.0 technology driver, by aggregating real-time data and transfer it to a centralised data hub, monitored regularly to protect patients. Blockchain technology can detect product anomalies, and recalls can be done even before the...
von Tobias Borgers | März 21, 2024 | Continuous Manufacturing
The pharmaceutical industry is confronting a variety of new and complex challenges in the face of globalization and changing market dynamics. The past decade has witnessed a decline in the discovery, approval and marketing of new chemical entities with fewer...
von Tobias Borgers | Feb. 14, 2024 | Boehringer
Boehringer Ingelheim is developing a biologicals development centre (BDC) at its facility in Biberach, Germany. Credit: Boehringer Ingelheim. A ground-breaking ceremony for the BDC was held in June 2018. Credit: Boehringer Ingelheim. BDC was inaugurated in April 2023....
von Tobias Borgers | Feb. 2, 2024 | Glaxo
When Matt Hill, PhD, was in graduate school, the human genome sequence was more or less finished and companies like 454 and Solexa were starting to make waves in next-gen sequencing (NGS). But Hill became more enamored with synthetic biology—engineering the genetic...
